Home » AGEB Journal » Issues » Volume 61" » Fasc.1 - Original articles » Article details

The shift in prevalence of hepatitis A immunity in Flanders, Belgium

Journal Volume 61 - 1998
Issue Fasc.1 - Original articles
Author(s) M. Beutels, P. Van Damme, R. Vranckx, A. Meheus
Full article
Full Article
VIEW FREE PDF
1 Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Community Medicine, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium 2 Institute of Hygiene and Epidemiology, J. Wytsmanstraat 14, 1050 Brussels, Belgium.

The purpose of this study was to obtain data on the prevalence of hepatitis A in Flanders, Belgium, in order to analyse any change in the epidemiological pattern of hepatitis A virus (HAV) in the region, and to determine at which age pre-vaccination testing would be useful. To meet these goals, a sero-epidemiological survey was conducted : 4058 serum samples were collected from a random sample of the general population in 1993-94. The overall age-standardised prevalence was 51.3%. Among non-Belgians (N = 245), the age-standardised anti-HAV prevalence was 66.4%, significantly higher than the 49.6% anti-HAV prevalence found in Belgians (N = 3186). Among Belgians, seroprevalence increased with age : from 5.4% in the youngest age group (0-14 years) to over 80% in the two oldest age groups (55-64 years and = 65 years). Prevalence rates were as high as 31.7% in the 25-34 year old age category, and 60.8% in the 35-44 year old age category. The age-specific prevalence figures among Belgians and nonBelgians reflect two different epidemiological patterns : the epidemiological pattern of a low endemic region for Belgians and the epidemiological profile of an intermediate endemic region for nonBelgians. The age-specific prevalence figures in Belgians were compared with the 1979 and 1989 anti-HAV prevalence figures in Belgian first-time blood donors. A clear epidemiological shift showing decreasing HAV prevalence in the youngest age groups was found. If we accept that pre-vaccination screening is useful at a 35% prevalence rate, all persons over 35 years of age should be screened before vaccination.

© Acta Gastro-Enterologica Belgica.